pamidronate has been researched along with Bone Demineralization, Pathologic in 4 studies
Bone Demineralization, Pathologic: Decrease, loss, or removal of the mineral constituents of bones. Temporary loss of bone mineral content is especially associated with space flight, weightlessness, and extended immobilization. OSTEOPOROSIS is permanent, includes reduction of total bone mass, and is associated with increased rate of fractures. CALCIFICATION, PHYSIOLOGIC is the process of bone remineralizing. (From Dorland, 27th ed; Stedman, 25th ed; Nicogossian, Space Physiology and Medicine, 2d ed, pp327-33)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the effect on the bone mineral density of a bisphosphonate (pamidronate) given intravenously, in combination with oral calcium and vitamin D supplements, compared with oral calcium and vitamin D supplements alone." | 2.71 | A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. ( Bartram, SA; Francis, RM; Peaston, RT; Rawlings, DJ; Thompson, NP, 2003) |
| "Pamidronate is a bisphosphonate whose short-term biological efficacy in Paget's disease of bone was convincingly established many years ago." | 2.69 | Effect of multiple intravenous pamidronate courses in Paget's disease of bone. ( Arlot, M; Meunier, PJ; Thevenon, J; Trombetti, A; Uebelhart, B, 1999) |
| "In the distal femur, a high-turnover renal osteodystrophy was found but pamidronate suppressed this bone turnover and increased bone mineral content." | 1.35 | Treatment of experimental renal osteodystrophy with pamidronate. ( Iwaniec, UT; Järvinen, TL; Jokihaara, J; Jolma, PM; Kannus, P; Kööbi, P; Mustonen, JT; Pörsti, IH; Saha, HH; Sievänen, H; Turner, RT, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Montangero, VE | 1 |
| Capiglioni, R | 1 |
| Roldán, EJ | 1 |
| Bartram, SA | 1 |
| Peaston, RT | 1 |
| Rawlings, DJ | 1 |
| Francis, RM | 1 |
| Thompson, NP | 1 |
| Jokihaara, J | 1 |
| Pörsti, IH | 1 |
| Kööbi, P | 1 |
| Jolma, PM | 1 |
| Mustonen, JT | 1 |
| Saha, HH | 1 |
| Sievänen, H | 1 |
| Kannus, P | 1 |
| Iwaniec, UT | 1 |
| Turner, RT | 1 |
| Järvinen, TL | 1 |
| Trombetti, A | 1 |
| Arlot, M | 1 |
| Thevenon, J | 1 |
| Uebelhart, B | 1 |
| Meunier, PJ | 1 |
2 trials available for pamidronate and Bone Demineralization, Pathologic
| Article | Year |
|---|---|
A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease.
Topics: Administration, Oral; Anti-Inflammatory Agents; Bone Demineralization, Pathologic; Bone Density; Cal | 2003 |
Effect of multiple intravenous pamidronate courses in Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bone Demineralization, Pathologic; Diphosp | 1999 |
2 other studies available for pamidronate and Bone Demineralization, Pathologic
| Article | Year |
|---|---|
Mandible and maxilla bone mineral density and threshold analysis studies by pQCT in two edentulous women receiving pamidronate.
Topics: Bone Demineralization, Pathologic; Bone Density; Bone Diseases, Metabolic; Bone Marrow; Calcificatio | 2003 |
Treatment of experimental renal osteodystrophy with pamidronate.
Topics: Animals; Bone Demineralization, Pathologic; Bone Density; Bone Remodeling; Chronic Kidney Disease-Mi | 2008 |